vs
Side-by-side financial comparison of Hologic (HOLX) and MSCI Inc. (MSCI). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $822.5M, roughly 1.3× MSCI Inc.). MSCI Inc. runs the higher net margin — 34.6% vs 17.1%, a 17.5% gap on every dollar of revenue. On growth, MSCI Inc. posted the faster year-over-year revenue change (10.6% vs 2.5%). MSCI Inc. produced more free cash flow last quarter ($488.7M vs $215.2M). Over the past eight quarters, MSCI Inc.'s revenue compounded faster (10.0% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
MSCI Inc. is an American finance company headquartered in New York City. MSCI is a global provider of equity, fixed income, real estate indices, multi-asset portfolio analysis tools, ESG and climate finance products. It operates the MSCI World, MSCI Emerging Markets, and MSCI All Country World (ACWI) indices, among others.
HOLX vs MSCI — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $822.5M |
| Net Profit | $179.1M | $284.7M |
| Gross Margin | 56.0% | — |
| Operating Margin | 22.6% | 56.4% |
| Net Margin | 17.1% | 34.6% |
| Revenue YoY | 2.5% | 10.6% |
| Net Profit YoY | -10.9% | -6.8% |
| EPS (diluted) | $0.79 | $3.81 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0B | $822.5M | ||
| Q3 25 | $1.0B | $793.4M | ||
| Q2 25 | $1.0B | $772.7M | ||
| Q1 25 | $1.0B | $745.8M | ||
| Q4 24 | $1.0B | $743.5M | ||
| Q3 24 | $988.0M | $724.7M | ||
| Q2 24 | $1.0B | $707.9M | ||
| Q1 24 | $1.0B | $680.0M |
| Q4 25 | $179.1M | $284.7M | ||
| Q3 25 | $187.2M | $325.4M | ||
| Q2 25 | $194.9M | $303.6M | ||
| Q1 25 | $-17.4M | $288.6M | ||
| Q4 24 | $201.0M | $305.5M | ||
| Q3 24 | $178.6M | $280.9M | ||
| Q2 24 | $194.5M | $266.8M | ||
| Q1 24 | $169.9M | $256.0M |
| Q4 25 | 56.0% | — | ||
| Q3 25 | 55.6% | — | ||
| Q2 25 | 56.3% | — | ||
| Q1 25 | 37.5% | — | ||
| Q4 24 | 56.8% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 55.4% | — | ||
| Q1 24 | 53.3% | — |
| Q4 25 | 22.6% | 56.4% | ||
| Q3 25 | 22.6% | 56.4% | ||
| Q2 25 | 24.9% | 55.0% | ||
| Q1 25 | -0.7% | 50.6% | ||
| Q4 24 | 22.5% | 54.5% | ||
| Q3 24 | 23.3% | 55.4% | ||
| Q2 24 | 24.1% | 54.0% | ||
| Q1 24 | 20.7% | 49.9% |
| Q4 25 | 17.1% | 34.6% | ||
| Q3 25 | 17.8% | 41.0% | ||
| Q2 25 | 19.0% | 39.3% | ||
| Q1 25 | -1.7% | 38.7% | ||
| Q4 24 | 19.7% | 41.1% | ||
| Q3 24 | 18.1% | 38.8% | ||
| Q2 24 | 19.2% | 37.7% | ||
| Q1 24 | 16.7% | 37.6% |
| Q4 25 | $0.79 | $3.81 | ||
| Q3 25 | $0.84 | $4.25 | ||
| Q2 25 | $0.86 | $3.92 | ||
| Q1 25 | $-0.08 | $3.71 | ||
| Q4 24 | $0.87 | $3.89 | ||
| Q3 24 | $0.75 | $3.57 | ||
| Q2 24 | $0.82 | $3.37 | ||
| Q1 24 | $0.72 | $3.22 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $515.3M |
| Total DebtLower is stronger | $2.5B | $6.2B |
| Stockholders' EquityBook value | $5.2B | $-2.7B |
| Total Assets | $9.2B | $5.7B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.4B | $515.3M | ||
| Q3 25 | $2.2B | $400.1M | ||
| Q2 25 | $1.9B | $347.3M | ||
| Q1 25 | $1.6B | $360.7M | ||
| Q4 24 | $2.0B | $409.4M | ||
| Q3 24 | $2.3B | $501.0M | ||
| Q2 24 | $2.4B | $451.4M | ||
| Q1 24 | $2.2B | $519.3M |
| Q4 25 | $2.5B | $6.2B | ||
| Q3 25 | $2.5B | $5.5B | ||
| Q2 25 | $2.5B | $4.5B | ||
| Q1 25 | $2.5B | $4.5B | ||
| Q4 24 | $2.5B | $4.5B | ||
| Q3 24 | $2.5B | $4.5B | ||
| Q2 24 | $2.5B | $4.5B | ||
| Q1 24 | $2.6B | $4.5B |
| Q4 25 | $5.2B | $-2.7B | ||
| Q3 25 | $5.0B | $-1.9B | ||
| Q2 25 | $4.8B | $-886.2M | ||
| Q1 25 | $4.6B | $-958.6M | ||
| Q4 24 | $4.8B | $-940.0M | ||
| Q3 24 | $5.1B | $-751.0M | ||
| Q2 24 | $5.0B | $-734.5M | ||
| Q1 24 | $4.8B | $-650.5M |
| Q4 25 | $9.2B | $5.7B | ||
| Q3 25 | $9.0B | $5.4B | ||
| Q2 25 | $8.8B | $5.4B | ||
| Q1 25 | $8.5B | $5.3B | ||
| Q4 24 | $8.7B | $5.4B | ||
| Q3 24 | $9.2B | $5.4B | ||
| Q2 24 | $8.9B | $5.5B | ||
| Q1 24 | $8.7B | $5.5B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | 0.52× | — | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.49× | — | ||
| Q2 24 | 0.51× | — | ||
| Q1 24 | 0.53× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $501.1M |
| Free Cash FlowOCF − Capex | $215.2M | $488.7M |
| FCF MarginFCF / Revenue | 20.5% | 59.4% |
| Capex IntensityCapex / Revenue | 1.4% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.28× | 1.76× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.5B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $229.9M | $501.1M | ||
| Q3 25 | $355.1M | $449.4M | ||
| Q2 25 | $343.3M | $336.1M | ||
| Q1 25 | $169.4M | $301.7M | ||
| Q4 24 | $189.3M | $430.6M | ||
| Q3 24 | $367.0M | $421.6M | ||
| Q2 24 | $405.8M | $349.2M | ||
| Q1 24 | $292.4M | $300.1M |
| Q4 25 | $215.2M | $488.7M | ||
| Q3 25 | $341.4M | $445.5M | ||
| Q2 25 | $330.5M | $324.7M | ||
| Q1 25 | $153.9M | $290.2M | ||
| Q4 24 | $172.5M | $416.4M | ||
| Q3 24 | $350.6M | $415.0M | ||
| Q2 24 | $385.3M | $340.6M | ||
| Q1 24 | $279.6M | $295.9M |
| Q4 25 | 20.5% | 59.4% | ||
| Q3 25 | 32.5% | 56.2% | ||
| Q2 25 | 32.3% | 42.0% | ||
| Q1 25 | 15.3% | 38.9% | ||
| Q4 24 | 16.9% | 56.0% | ||
| Q3 24 | 35.5% | 57.3% | ||
| Q2 24 | 38.1% | 48.1% | ||
| Q1 24 | 27.5% | 43.5% |
| Q4 25 | 1.4% | 1.5% | ||
| Q3 25 | 1.3% | 0.5% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 1.5% | 1.5% | ||
| Q4 24 | 1.6% | 1.9% | ||
| Q3 24 | 1.7% | 0.9% | ||
| Q2 24 | 2.0% | 1.2% | ||
| Q1 24 | 1.3% | 0.6% |
| Q4 25 | 1.28× | 1.76× | ||
| Q3 25 | 1.90× | 1.38× | ||
| Q2 25 | 1.76× | 1.11× | ||
| Q1 25 | — | 1.05× | ||
| Q4 24 | 0.94× | 1.41× | ||
| Q3 24 | 2.05× | 1.50× | ||
| Q2 24 | 2.09× | 1.31× | ||
| Q1 24 | 1.72× | 1.17× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
MSCI
| Recurring Subscriptions | $246.4M | 30% |
| Asset Based Fees | $211.7M | 26% |
| Analytics Segment | $182.3M | 22% |
| Sustainability And Climate Segment | $90.3M | 11% |
| Other | $70.9M | 9% |
| Non Recurring | $21.1M | 3% |
